Trial · NCT00962429
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
NCT00962429, Phase 2, Completed, Oregon Health and Science University; results first posted 2020-08-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy. Trials, record NCT00962429. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00962429
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
- NCT number
- NCT00962429
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 7 participants, actual
- Lead sponsor
- Oregon Health and Science University
- Conditions
- CIDP, Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- lipoic acid
- First posted
- 2009-08-20
- Last updated
- 2020-08-19
- Results first posted
- 2020-08-19
- Limitations and caveats
The Responsible Party has left the institution and has indicated that they do not have the raw data. They've confirmed that, despite all efforts to locate the data by contacting study team members, efforts were unsuccessful and no data are available.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Muscle Strength | 16 weeks | |
| Secondary | Hughes Functional Disability Scale | 16 weeks | |
| Secondary | Forced Vital Capacity (FVC) | 16 weeks | |
| Secondary | Motor Nerve Conduction Studies (NCS) | 16 weeks |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Muscle Strength | 16 weeks | The Responsible Party has left the institution and has indicated that they do not have the raw data. They have confirmed that, despite all efforts to locate the data by contacting study team members, efforts were unsuccessful and no data are available. | ||
| SECONDARY | Hughes Functional Disability Scale | 16 weeks | The Responsible Party has left the institution and has indicated that they do not have the raw data. They have confirmed that, despite all efforts to locate the data by contacting study team members, efforts were unsuccessful and no data are available. | ||
| SECONDARY | Forced Vital Capacity (FVC) | 16 weeks | The Responsible Party has left the institution and has indicated that they do not have the raw data. They have confirmed that, despite all efforts to locate the data by contacting study team members, efforts were unsuccessful and no data are available. | ||
| SECONDARY | Motor Nerve Conduction Studies (NCS) | 16 weeks | The Responsible Party has left the institution and has indicated that they do not have the raw data. They have confirmed that, despite all efforts to locate the data by contacting study team members, efforts were unsuccessful and no data are available. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Lipoic Acid | 0 | |
| Overall Study | STARTED | Placebo | 0 | |
| Overall Study | COMPLETED | Lipoic Acid | 0 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Lipoic Acid | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Lipoic Acid | 0 | 0 |
| Total, all-cause mortality | Placebo | 0 | 0 |
| Total, other adverse events | Lipoic Acid | 0 | 0 |
| Total, other adverse events | Placebo | 0 | 0 |
| Total, serious adverse events | Lipoic Acid | 0 | 0 |
| Total, serious adverse events | Placebo | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00962429
GET https://conductscience.org/api/trials/v1/NCT00962429/registered